Slow-moving vaccines in FY22 pushes Pharmaniaga to PN17 status
KUALA LUMPUR (Feb 28): Pharmaniaga Bhd has posted a net loss of RM607.32 million for the financial year ended Dec 31, 2022 (FY22) against a net profit of RM172.15 million in the previous year, with a RM552 million provision for “slow-moving stocks of Covid-19 vaccines” pushing the company under the financially troubled PN17 category. Revenue [...]
Tags : moving vaccines pushes pharmaniaga status
Disclaimer : We make no assurance about the completeness and accuracy of the content of this website. All news on this website is collected from various sources hence information may or may not be true. Money Nations does not verify the reliability of the content published. We do not accept any accountability for loss or damage occurred as a result of reliability on the content of this website.